e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 14, 2008
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of incorporation or organization) 		  0-26770
(Commission File Number) 		  22-2816046
(I.R.S. Employer Identification No.)
         
9920 Belward Campus Drive
Rockville, Maryland
(Address of principal executive offices) 		      20850
(Zip Code)
         
Registrant’s telephone number, including area code:       (240) 268-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01 Regulation FD Disclosure.
On January 14, 2008, Novavax, Inc. (the “Company”) posted a corporate presentation to its website. The Company expects to use the corporate presentation at certain investor meetings beginning on January 14, 2008. The presentation contains statements that are “forward-looking statements” subject to the cautionary statement about forward-looking statements set forth therein.
A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
     (d) Exhibits
Exhibits
     99.1 Corporate Presentation of Novavax, Inc.

2

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
             
    Novavax, Inc.    
    (Registrant)    
 
            
January 14, 2008
  By:
Name: 		  /s/ Len Stigliano
 
Len Stigliano 		   
 
  Title:   Chief Financial Officer, Vice President and Treasurer    

3